stockrow
Friday 6 November 2026
Export CASIF’s income statement to Excel — free account
CASI Pharmaceuticals Inc.
CASIF Healthcare Biotechnology
CASI Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.7 million, down 27.4% from fiscal 2024.
- Revenue
- −45.9%
- EPS
- +35.8%
- Free cash flow
- −23,251.7%
- Total debt
- +6.97%
Quarter to December 2025, against a year earlier
0.11
0.01
+10.00%
Follow CASIF
Alert me
CASI Pharmaceuticals Inc. (CASIF) P/E ratio
CASI Pharmaceuticals Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| 25 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TVRD Tvardi Therapeutics, Inc. compare | n/m |
| HIND Vyome Holdings, Inc. compare | n/m |
| GUTS Fractyl Health, Inc. compare | n/m |
| LPCN Lipocine Inc. compare | n/m |
| TCRX TScan Therapeutics, Inc. compare | n/m |
| BCDA BioCardia, Inc. compare | n/m |
| CASIF CASI Pharmaceuticals Inc. | n/m |
| DARE Dare Bioscience, Inc. compare | n/m |
| BOLT Bolt Biotherapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)